Deverra Therapeutics is dedicated to developing allogeneic universal donor cellular immunotherapies that are cost effective and accessible to all patients.
Our platform technology uses sustainable, healthy donor umbilical cord blood cells to generate universal cell therapies, meaning no donor-patient matching is needed.
Our platform is capable of generating many distinct cell types resulting in a diverse pipeline of cell therapies for multiple indications.
Our scalable manufacturing and effective cryopreservation enables delivery of
ready-made therapies for immediate, on-demand use.
We have 20+ years of experience in developing allogeneic off-the-shelf therapies based on federally funded research and across five clinical trials to date.
We pioneered the development of cell therapies accessible for all patients with no matching required
We provide treatment options for newly diagnosed AML patients with our hematopoietic stem & progenitor cell immunotherapy.
Dilanubicel, our lead product, has been evaluated in a global phase 2 randomized controlled trial in patients with newly diagnosed AML. Data from this study demonstrated a statistically significant increase in remission rates in patients who received dilanubicel as an adjuvant to standard of care chemotherapy when compared to patients who received standard of care chemotherapy alone.
We generate natural killer (NK) cells and myeloid cells (monocytes and macrophages) that can be used to fight cancer and to boost immunity against viral infections.
DVX201, our unmodified NK cell product, has been safely dosed in two Phase 1 clinical trials which have now been licensed to our partner, Coeptis Therapeutics. Our goal is to create families of NK cell and myeloid cell therapies, both unmodified and engineered to enhance their innate potency and to target specific cancers (e.g., cytokine or CAR/TCR expression). We aim to use these individual cell therapies alone or in combination with each other to mimic the natural immune system that does not work by one cell type alone.
We aim to target blood cancers and solid tumors using our CAR-NK cells and the patient’s own immune system activated by our myeloid cell product.
In addition to engineering NK cells to target specific cancers (CAR-NKs), our goal is to develop engineered monocyte/macrophage therapies to treat patients with solid tumors, alone or in combination with other cell therapy products, generated off our platform.